25 noviembre 2014
Experimental anti-cancer agents PF-04691502 and PD-0325901 excel in lab tests against colorectal cancer models and enter phase 1 trial, scientists report. «This study demonstrates strong potential for this combination in treating laboratory models of colorectal cancer. We hope that if we can discover biomarkers that predict which tumors respond and which don’t respond to the combination that we can optimize its use,» one researcher says.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/C-tzVI8CeyY/141125091141.htm
